ChemoCentryx is a biopharmaceutical company commercializing and developing new medications for inflammatory and autoimmune diseases and cancer.
ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies.
In the United States, ChemoCentryx markets TAVNEOS™ (avacopan), the first approved orally-administered inhibitor of the complement 5a receptor as an adjunctive treatment for adult patients with severe active ANCA-associated vasculitis.
The approval of Tavenos by the FDA is the company’s first in its 24 year history. Of the 50,000 vasculitis patients in the United States, ChemoCentryx estimates that 9,500 fit Tavneos’ label.
Through its partnership with ChemoCentryx, Amber Specialty Pharmacy’s best-in-class service model will support autoimmune specialists, rheumatologists and patients throughout the country.
As the nation’s leading rare pharmacy, PANTHERx supports tens of thousands of patients across the country with 25+ uniquely customized RxARECARE® programs. These highly specialized teams utilize their clinical expertise with our proprietary SWFT® technology system to address the specific needs of every patient we serve.
Takeaway: ChemoCentryx selected only Amber Specialty Pharmacy and PANTHERx as its limited distribution network for Tavenos